Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

Lung Cancer. 2019 Jan:127:169-171. doi: 10.1016/j.lungcan.2018.11.018. Epub 2018 Nov 14.

Authors

Affiliations

¹ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: ichidai@med.nagoya-u.ac.jp.
² Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
³ Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.

PMID: 30477806
DOI: 10.1016/j.lungcan.2018.11.018

No abstract available

Publication types

Letter

MeSH terms

Adult
Afatinib / therapeutic use*
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / drug therapy*
Male
Middle Aged
Mutation / genetics*
Neoplasm Staging
Retrospective Studies

Substances

Antineoplastic Agents
Afatinib
EGFR protein, human
ErbB Receptors